抄録
Healthy subjects and patients with bronchial asthma complicated by nasal allergy were involved in the study. Beclomethasone dipropionate inhaler (BDI) and beclomethasone dipropionate nasal spray (BDN) were given by oral or nasal inhalation in a total dose of 800μg daily. Pituitary-adrenal function was studied before administration and two and four weeks after administration.
As far as healthy subjects were concerned, neither those in Group A who inhaled 400μg/day of BDI and 400μg/day of BDN (total dose, 800μg/day) nor those in Group B who inhaled 800μg/day of BDN showed significant changes in the insulin tolerance test and urinary 17-OHCS excretion. The serum levels of immuno-reactive beclomethasone (IR-beclomethasone) after administration significantly increased in Group A and tended to increase in Group B as compared with that before administration.
Patients seemed to show a lower level of plasma ACTH before administration than healthy subjects. Concurrent inhalation of BDI and BDN tended to decrease neither plasma ACTH nor serum cortisol. Serum IR-beclomethasone showed no remarkable increase after administration. This was possibly because mouth wash by means of “gargling” prevented the absorption of beclomethasone from oral and pharyngeal membranes.
It was considered that the inhalation of BDI and BDN in a dose of 800μg daily had no effect on the pituitary-adrenal axis.
